Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Despite the advent of safe and effective coronavirus disease 2019 vaccines, pervasive inequities in global vaccination persist.
METHODS: We projected health benefits and donor costs of delivering vaccines for up to 60% of the population in 91 low- and middle-income countries (LMICs). We modeled a highly contagious (Re at model start, 1.7), low-virulence (infection fatality ratio [IFR], 0.32%) "Omicron-like" variant and a similarly contagious "severe" variant (IFR, 0.59%) over 360 days, accounting for country-specific age structure and healthcare capacity. Costs included vaccination startup (US$630 million) and per-person procurement and delivery (US$12.46/person vaccinated).
RESULTS: In the Omicron-like scenario, increasing current vaccination coverage to achieve at least 15% in each of the 91 LMICs would prevent 11 million new infections and 120 000 deaths, at a cost of US$0.95 billion, for an incremental cost-effectiveness ratio (ICER) of US$670/year of life saved (YLS). Increases in vaccination coverage to 60% would additionally prevent up to 68 million infections and 160 000 deaths, with ICERs <US$8000/YLS. ICERs were <US$4000/YLS under the more severe variant scenario and generally robust to assumptions about vaccine effectiveness, uptake, and costs.
CONCLUSIONS: Funding expanded COVID-19 vaccine delivery in LMICs would save hundreds of thousands of lives, be similarly or more cost-effective than other donor-funded global aid programs, and improve health equity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:226 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 226(2022), 11 vom: 28. Nov., Seite 1887-1896 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siedner, Mark J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVAX |
|---|
| Anmerkungen: |
Date Completed 30.11.2022 Date Revised 30.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiac243 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342181351 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342181351 | ||
| 003 | DE-627 | ||
| 005 | 20231226013514.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiac243 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342181351 | ||
| 035 | |a (NLM)35696544 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Siedner, Mark J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2022 | ||
| 500 | |a Date Revised 30.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Despite the advent of safe and effective coronavirus disease 2019 vaccines, pervasive inequities in global vaccination persist | ||
| 520 | |a METHODS: We projected health benefits and donor costs of delivering vaccines for up to 60% of the population in 91 low- and middle-income countries (LMICs). We modeled a highly contagious (Re at model start, 1.7), low-virulence (infection fatality ratio [IFR], 0.32%) "Omicron-like" variant and a similarly contagious "severe" variant (IFR, 0.59%) over 360 days, accounting for country-specific age structure and healthcare capacity. Costs included vaccination startup (US$630 million) and per-person procurement and delivery (US$12.46/person vaccinated) | ||
| 520 | |a RESULTS: In the Omicron-like scenario, increasing current vaccination coverage to achieve at least 15% in each of the 91 LMICs would prevent 11 million new infections and 120 000 deaths, at a cost of US$0.95 billion, for an incremental cost-effectiveness ratio (ICER) of US$670/year of life saved (YLS). Increases in vaccination coverage to 60% would additionally prevent up to 68 million infections and 160 000 deaths, with ICERs <US$8000/YLS. ICERs were <US$4000/YLS under the more severe variant scenario and generally robust to assumptions about vaccine effectiveness, uptake, and costs | ||
| 520 | |a CONCLUSIONS: Funding expanded COVID-19 vaccine delivery in LMICs would save hundreds of thousands of lives, be similarly or more cost-effective than other donor-funded global aid programs, and improve health equity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVAX | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a cost-effectiveness | |
| 650 | 4 | |a health equity | |
| 650 | 4 | |a low and middle-income countries | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Alba, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzmaurice, Kieran P |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Rebecca F |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Justine A |e verfasserin |4 aut | |
| 700 | 1 | |a Shebl, Fatma M |e verfasserin |4 aut | |
| 700 | 1 | |a Ciaranello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Krishna P |e verfasserin |4 aut | |
| 700 | 1 | |a Freedberg, Kenneth A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 226(2022), 11 vom: 28. Nov., Seite 1887-1896 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:226 |g year:2022 |g number:11 |g day:28 |g month:11 |g pages:1887-1896 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiac243 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 226 |j 2022 |e 11 |b 28 |c 11 |h 1887-1896 | ||